Assessment of HER2 status in breast cancer biopsies is not affected by accelerated tissue processing.
Joris P BulteAltuna HalilovicShona KalkmanPatricia H J van CleefPaul J van DiestLuc J A StrobbeJohannes H W de WiltPeter BultPublished in: Histopathology (2018)
HER2 status can be determined reliably on CNB specimens with accelerated processing time using standard clinical testing methods. Using this accelerated technology the minimum 6 h of formalin fixation, which current guidelines consider necessary, can be decreased safely. This allows for a complete and expedited histology-based diagnosis of breast lesions in the setting of a one-stop-shop, same-day breast clinic.